ReviewAddiction science & clinical practice2024
Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.
Review in Addiction science & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Non-invasive liver fibrosis screening and referral patterns in women with dependence due to psychoactive substance use: A single-centre retrospective study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Culturally tailored steatotic liver disease management: Latino and Asian community partner perspectives and recommendations.Hepatology communications · 2025Article
- Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease.Alimentary pharmacology & therapeutics · 2025Article
- Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis.Alcohol, clinical & experimental research · 2025Article
- The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on "The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study".Clinical and molecular hepatology · 2025Article
- Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis.Internal and emergency medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alcohol-associated liver disease is currently the leading cause of liver transplantation and liver deaths both in Europe and the United States. Efficacious treatments exist for alcohol use disorder, but they are seldomly prescribed for patients who need them. Besides, the presence of liver cirrhosis can complicate pharmacological treatment choices. In this review, we discuss established and innovative treatment strategies to treat unhealthy alcohol use in patients with alcohol-associated liver disease. We also describe the experience of our own institutions, Hospital Universitari Germans Trias i Pujol in Badalona (Spain) and Yale-New Haven Health and Yale Medicine (Connecticut. United States of America).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.